Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma

Dipenkumar Modi, Seongho Kim, Silva Pregja, Christiane Houde, Kathy A. Reichel, Rod Ramchandren

Blood (2021) 138 (Supplement 1): 3561.

https://doi.org/10.1182/blood-2021-149793

Published: 2021

Journal Articles

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

Jeffrey A Zonder, MD, Vaishali Sanchorawala, MD, Vishal Kukreti, MD FRCP(C), Sascha A Tuchman, MD, Yubin Kang, MD, Divaya Bhutani, MD, Steven Burt, ANP, Christiane Houde, BS, Kathy A. Reichel, Silva Pregja, MBA, Jeffrey V Matous, MD

Blood (2017) 130 (Supplement 1): 3158.

https://doi.org/10.1182/blood.V130.Suppl_1.3158.3158

Published: 2017

Journal Articles

A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Radhakrishnan Ramchandren, MD, Tycel J. Phillips, MD, Sumana Devata, MD, Ali M. Gabali, MD PhD, Christiane Houde, BS, Silva Pregja, MBA, Golbon Aghamohammadi, MSN,ANP-BC, Emily Wesson, NP, Tony Hutto, BS, Michelle A. Fanale, MD

Blood (2017) 130 (Supplement 1): 1527.

https://doi.org/10.1182/blood.V130.Suppl_1.1527.1527

Published: 2017

Journal Articles

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study

Galina G. Lagos, MD, Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey A Zonder, MD, Keren Osman, MD, Julia Gould, BA, Wei-Yann Tsai, PhD, Silva Pregja, MBA, Mariamne Reyna, BS, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 1838.

https://doi.org/10.1182/blood.V130.Suppl_1.1838.1838

Published: 2017

Journal Articles

Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis

Galina Grigoriev Lagos, MD, Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey Zonder, MD, Keren Osman, MD, Julia Gould, BA, Wei-Yann Tsai, Silva Pregja, MBA, Mariamne Reyna, BS, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2016) 128 (22): 4523.

https://doi.org/10.1182/blood.V128.22.4523.4523

Published: 2016

Journal Articles

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Jeffrey Zonder, MD, Christiane Houde, BS, Sascha Tuchman, MD, Vishal Kukreti, MD, Vaishali Sanchorawala, MD, Silva Pregja, MBA, Kathy A Reichel, Steven M Burt, NP, Colleen Neveux, RN, Jeffrey Matous, MD

Blood (2014) 124 (21): 4767.

https://doi.org/10.1182/blood.V124.21.4767.4767

Published: 2014

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Beverly Harrison, Kenneth C. Anderson, MD, Noopur Raje, MD, Paul Richardson, MD, Diane Warren, Ajai Chari, MD, Sundar Jagannath, MD, Lisa La, Jesus Berdeja, MD, Meredith Zimlich, Joseph W. Fay, MD, Sheila Powell, RN, Craig C Hofmeister, MD, Nita Williams, BS, Andrzej J. Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Kathryn McDonnell, Amrita Y. Krishnan, MD, Lupe Duarte, CCRC, Shaji K Kumar, MD, Ann Birgin, CRA, Sagar Lonial, M.D., Kenisha Baron, Thomas Martin, MD, Jeffrey L Wolf, MD, Geraldine Pelle-Day, Ph.D., Glenna Auerback, Gregory Orloff, MD, Nikki Hodge, Donna E Reece, MD, FRCPC, Suzanne Trudel, MD, Engin Gul, HonBSc, Vivek Roy, M.D., Michele Maharaj, RN, David S. Siegel, MD, PhD, Adolfo Aleman, A. Keith Stewart, Rachel Hagerty, Moshe Talpaz, MD, Roxane Collins, Ravi Vij, MD, Mark A. Fiala, BS, CCRP, Jeffrey Zonder, M.D., Silva Pregja, Sharon Goldberg, Joan Levy, PhD, Karen Dietz, Walter Capone, Daniel Auclair, PhD, Anne Quinn Young, Kathy Giusti, MBA

Blood (2013) 122 (21): 5388.

https://doi.org/10.1182/blood.V122.21.5388.5388

Published: 2013

NARROW

A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study

Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study

Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only